Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Gaush Meditech Ltd. ( (HK:2407) ) has issued an update.
Gaush Meditech Ltd. reported 2025 revenue of RMB1.38 billion, down 3.4% year on year, while net profit inched up 3.1% to RMB91.2 million and basic earnings per share rose to RMB0.66. Despite softer top-line performance, the company increased research and development spending by 18.1% to RMB92.6 million, lifting R&D to 6.7% of revenue and signaling a continued focus on innovation, but the board decided against a final dividend for 2025 after paying HK$0.3 per share a year earlier, indicating a preference for reinvestment over immediate shareholder payouts.
The most recent analyst rating on (HK:2407) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Gaush Meditech Ltd. stock, see the HK:2407 Stock Forecast page.
More about Gaush Meditech Ltd.
Gaush Meditech Ltd. is a Cayman Islands–incorporated medical technology company listed in Hong Kong that focuses on developing and selling ophthalmic and related medical devices. The group targets the healthcare sector with a product portfolio supported by sustained investment in research and development to maintain technological competitiveness and address demand in its niche markets.
Average Trading Volume: 41,901
Technical Sentiment Signal: Sell
Current Market Cap: HK$945M
For an in-depth examination of 2407 stock, go to TipRanks’ Overview page.